...
首页> 外文期刊>Radiation oncology >Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients
【24h】

Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients

机译:用于晚期辐射诱导的组织毒性的高压氧疗法:乳腺癌患者的前瞻性患者报告的结果措施

获取原文
           

摘要

Introduction This study examines patient reported outcome measures of women undergoing hyperbaric oxygen treatment (HBOT) after breast-conserving therapy. Method Included were 57 women treated with HBOT for late radiation-induced tissue toxicity (LRITT) referred in the period January 2014-December 2015. HBOT consisted of (on average) 47 sessions. In total, 80?min of 100?% O2 was administered under increased pressure of 2.4 ATA. Quality of life was assessed before and after treatment using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23, and a NRS pain score. Results Fifty-seven women were available for evaluation before and after treatment. Before HBOT, patients had severe complaints of pain in the arm/shoulder (46?%), swollen arm/hand (14?%), difficulty to raise arm or move it sideways (45?%), pain in the area of the affected breast (67?%), swollen area of the affected breast (45?%), oversensitivity of the affected breast (54?%), and skin problems on/in the area of the affected breast (32?%); post HBOT, severe complaints were still experienced in 17, 7, 22, 15, 13, 15, and 11?% of the women, respectively. Differences were all significant. The NRS pain score improved at least 1 point (range 0–10) in 81?% of the patients ( p Conclusion In these breast cancer patients treated with HBOT for LRITT, the patient-reported outcomes were positive and improvements were observed. HBOT was a well-tolerated treatment for LRITT and its side-effects were both minimal and reversible.
机译:简介本研究检测患者报告哺乳治疗后患有高压氧治疗(HBOT)的妇女的结果测量。包括在2014年1月期间提到的晚期辐射诱导的组织毒性(LRITT)治疗的57名妇女治疗,2015年1月期间提到.HBOT由(平均)47个会议组成。总共80?min 100?%O 2 在增加2.4 ATA的压力下施用。在使用欧洲研究和治疗癌症(EORTC)QLQ-BR23的研究和治疗之前和治疗之前和之后评估生活质量,并进行NRS疼痛评分。结果在治疗前后可评估57名女性。在HBOT之前,患者在手臂/肩部(46?%)疼痛的严重投诉(46?%),肿胀的臂/手(14?%),难以抬起臂或侧向移动它(45?%),疼痛受影响的乳房(67〜%),受影响的乳房的肿胀面积,受影响的乳房的过敏(54℃)和受影响的乳房面积上的皮肤问题(32?%);在HBOT后,严重投诉仍然在17,7,22,15,13,​​15和11名妇女中经历过。差异都很重要。 NRS疼痛评分在81岁的患者中提高至少1点(范围0-10)(在这些乳腺癌患者中对LRITT治疗的这些乳腺癌患者,患者报告的结果是阳性的,并且观察到改善。HBOT是对LRITT的耐受良好的处理及其副作用既有最小又可逆。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号